Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer

BACKGROUND: Castration resistant prostate cancer (CRPC) is a leading cause of cancer-related deaths in men. The primary cause of mortality and morbidity in patients is bone metastases and remodeling resulting in osteoblastic and osteolytic lesions. Recently, cabozantinib, a multi-kinase inhibitor (V...

Descripción completa

Detalles Bibliográficos
Autores principales: Eswaraka, Jeetendra, Giddabasappa, Anand, Han, Guangzhou, Lalwani, Kush, Eisele, Koleen, Feng, Zheng, Affolter, Timothy, Christensen, James, Li, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190397/
https://www.ncbi.nlm.nih.gov/pubmed/25277255
http://dx.doi.org/10.1186/1471-2407-14-742

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190397/
https://www.ncbi.nlm.nih.gov/pubmed/25277255
http://dx.doi.org/10.1186/1471-2407-14-742

Ejemplares similares